On 26 January 2017 Actelion and Johnson & Johnson announced that they have entered into a definitive transaction agreement under which Johnson & Johnson will launch an all-cash tender offer in Switzerland to acquire all of the outstanding shares of Actelion.

Find all information and updates concerning the proposed transaction on this page

Definitive notice of the end result of the tender offer

27 April 2017:

Johnson & Johnson published the definitive notice of the end result of their tender offer for Actelion.

Provisional notice of the end result of the tender offer

24 April 2017:

Johnson & Johnson published the provisional notice of the end result of their tender offer for Actelion.

Annual General Meeting 2017

5 April 2017

At today's Annual General Meeting of Shareholders held in Allschwil, shareholders approved demerger of Actelion's drug discovery and early clinical pipeline to form new company Idorsia.

Definitve Results for Interim Tender Offer

5 April 2017:

Johnson & Johnson published the definitve results of their iterim tender offer for Actelion.

Provisional Results for Interim Tender Offer

31 March 2017:

Johnson & Johnson published the interim results of their tender offer for Actelion.

Invitation Annual General Meeting

15 March 2017:

Actelion published it's invitation for the Annual General Meeting 2017 which will be held on Wednesday 5 April 2017.

Johnson & Johnson Prospectus

16 February 2017:

Johnson & Johnson published the prospectus for their tender offer for Actelion.

Annual Report 2016

14 February 2017:

Actelion published its Annual Report.

Pre-Announcement Tender Offer

26 January 2017:

Actelion and Johnson & Johnson entered into a definitive transaction agreement.

Contact

Investor Relations
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
CH-4123 Allschwil
Switzerland
Contact
Tel.: +41 61 565 62 62
Fax: +41 61 565 65 07
Contact us online